Skip to main content
. 2022 Jan 11;7:11. [Version 1] doi: 10.12688/wellcomeopenres.16986.1

Figure 3. Clinical experience with anti-TNF (tumour necrosis factor) in Niemann-Pick Type C patients with inflammatory bowel disease (IBD).

Figure 3.

A: Disease activity over time in patients 2, 3 and 4. Time points “0” indicated baseline disease activity before start of infliximab. Disease activity was determined by mathematically weighted Pediatric Crohn’s Disease Activity Index (wPCDAI, range 0-125 points). B: Anti-TNF therapy results in marked improvement of severe perianal disease in patient 2.